Du är här

2014-05-02

Dako Denmark A/S: Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis

GLOSTRUP, Denmark, May 2, 2014. Dako, an Agilent Technologies company
and worldwide provider of cancer diagnostic solutions
, today announced the addition of two new antibodies,
Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents,
instruments and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin
8/18 (CK 8/18) available from a major pathology provider. It is used by
pathologists to stain CK 8/18 in tissue samples and thereby help classify
tumors of unknown origin. Keratins are one of the most potent epithelial
differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma
and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in
tissue samples. In immunohistochemistry, antibodies to TdT can be used to
demonstrate the presence of pre-T and pre-B cells and multipotent
hematopoietic stem cells that possess the antigen.

Both Anti-CK 8/18 and Anti-TdT provide excellent specificity and sensitivity
and have been reviewed and accepted by key pathology experts. Both antibodies
provide optimal staining results enabled by the FLEX Ready-to-Use Dako
solutions.

FLEX Ready-to-Use is a plug-and-play solution consisting of pre-diluted
antibodies, a visualization system, and optimized validated protocols
developed in collaboration with leading pathology experts. The protocols are
developed to take into account pre-analytical variations and different ways
of processing and handling tissue samples, ensuring optimal staining results
for pathology labs.

"With the FLEX RTU solution, it takes less time for a lab to validate new
antibodies for routine diagnostic use," said Hans Christian Pedersen, global
product manager, Dako IHC reagents. "FLEX Ready-to-Use antibodies are helping
labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive
offering to pathologists around the world," said Britt Meelby Jensen, vice
president of Marketing and Pathology Sales in Agilent's Diagnostics and
Genomics business. "One of our goals is to constantly establish new quality
benchmarks within IHC reagents."

Both products are available from Dako now as 1.0 mL concentrates and 12 mL (60
tests) FLEX RTUs for Autostainer Link 48.

Editorial Contacts

Dako Products and Solutions for Pathology
Victoria Wadsworth-Hansen
victoria.wadsworth-hansen@agilent.com

+45 29336980

Media and Press
Maia Fredtoft Søchting
maia.sochting@agilent.com

+45 25461083

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,600 employees serve
customers in more than 100 countries. Agilent had revenues of $6.8 billion in
fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of
reagents, instruments, software and expertise to make accurate diagnoses and
determine the most effective treatment for cancer patients. Information about
Agilent is available atwww.agilent.comand information about Dako products is
available atwww.dako.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic measurement
business. The new company is named Keysight Technologies, Inc. The separation
is expected to be completed in early November 2014.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Dako Denmark A/S via Globenewswire

HUG#1782272

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.